Assigning the effect of administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009154755N1

Enrollment

Registered

2011-01-04

Start date

2010-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome. POLYCYSTIC OVARY

Interventions

Intervention 1: Cabergoline, 0.5 mg tablets, weekly for 12 weeks. Intervention 2: to the placebo group placebo tablets similar to cabergoline 0.5 mg for 12 weeks, a week is given a pill.

Treatment - Drugs

Placebo

Cabergoline, 0.5 mg tablets, weekly for 12 weeks

to the placebo group placebo tablets similar to cabergoline 0.5 mg for 12 weeks, a week is given a pill

Eligibility

Sex/Gender

Female

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 20 years, living in Sanandaj Exclusion criteria: pregnancy, breastfeeding, contraindication or adverse effects of cabergoline (nausea, vomiting, visual disturbances)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Uterine blood flow. Timepoint: Baaseline and after 12 weeks. Method of measurement: According mm by Doppler ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSayedeh Reyhaneh Yousefi

Kurdistan University of Medical Sciences

rey.yousefi@muk.ac.ir+98 87 1328 5910

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026